Evidence map›Paper›PMID 34597353›Full record

ArticlePloS one2021

Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.

Shunsuke Tsuzuki, Shotaro Nakanishi, Mitsuyoshi Tamaki, Takuma Oshiro, Jun Miki, Hiroki Yamada, Tatsuya Shimomura, Takahiro Kimura, Nozomu Furuta, Seiichi Saito and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Shunsuke TsuzukiDepartment of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.ORCID 0000-0001-6164-4684
Shotaro NakanishiDepartment of Urology, University of the Ryukyus, Graduate School of Medicine, Nishihara, Okinawa, Japan.
Mitsuyoshi TamakiDepartment of Urology, University of the Ryukyus, Graduate School of Medicine, Nishihara, Okinawa, Japan.
Takuma OshiroDepartment of Urology, University of the Ryukyus, Graduate School of Medicine, Nishihara, Okinawa, Japan.
Jun MikiDepartment of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
Hiroki YamadaDepartment of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
Tatsuya ShimomuraDepartment of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
Takahiro KimuraDepartment of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
Nozomu FurutaDepartment of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
Seiichi SaitoDepartment of Urology, University of the Ryukyus, Graduate School of Medicine, Nishihara, Okinawa, Japan.
Shin EgawaDepartment of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
Jikei University School of Medicine · JPUniversity of the Ryukyus · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere was no clear evidence whether the initial dose of enzalutamide affects the incidence of adverse events (AEs), and oncological outcome in patients with castration-resistant prostate cancer (CRPC).

methodsThe clinical charts of 233 patients with CRPC treated with enzalutamide were reviewed retrospectively. After 1:3 propensity score matching (PSM), 124 patients were divided into a reduced dose group and a standard dose group, and the prostate specific antigen (PSA) response and the incidence of AEs were compared.

results190 patients with CRPC initiated with standard dose enzalutamide were younger and better performance status compared with 43 patients beginning with reduced dose. After PSM, the baseline characteristics were not different between the standard and the reduced dose group. In the PSM cohort, the PSA response rate was significantly lower in the reduced dose group than in the standard dose group (-66.3% and -87.4%, p = 0.02). The incidence rates of AEs were not statistically different between the groups (22.6% and 34.4%, respectively, p = 0.24).

conclusionInitiating treatment with a reduced dose of enzalutamide did not significantly decrease the incidence rate of AEs, and it showed poorer PSA response rate. There is no clear rationale for treating with a reduced initial dose of enzalutamide to reduce the incidence of AEs.

Indexed as

AgedAged, 80 and overAntineoplastic AgentsBenzamidesCohort StudiesDose-Response Relationship, DrugDrug-Related Side Effects and Adverse ReactionsHumansMaleNitrilesPhenylthiohydantoinProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantRetrospective StudiesTreatment OutcomeAntineoplastic AgentsBenzamidesenzalutamideNitrilesPhenylthiohydantoinProstate-Specific Antigen

Identifiers

PMID34597353
PMCPMC8486121
OpenAlexW3202797731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.